Properties (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
patisiran
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C40H61N3O12P
|
| gptkbp:clinicalTrials |
Phase 3
APOLLO trial |
| gptkbp:dosageForm |
lipid nanoparticles
|
| gptkbp:formulation |
sterile solution
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Onpattro
|
| gptkbp:lastProduced |
2018
|
| gptkbp:mandates |
polyneuropathy of hereditary transthyretin-mediated amyloidosis
|
| gptkbp:manufacturer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:European_Union
gptkb:United_States |
| gptkbp:route |
intravenous
|
| gptkbp:sells |
gptkb:Onpattro
|
| gptkbp:sideEffect |
infusion-related reactions
|
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
RNA interference
|
| gptkbp:usedFor |
treatment of hereditary transthyretin amyloidosis
|